Amol Akhade: Breaking Free from the Hazard Ratio

Amol Akhade shared on LinkedIn:

“While reading came across this editorial by Larry Han from last year in NEJM about Hazard Ration and RMST .

What do u mean when HR is 0.7?
When do u need RMST?
How to interpret it ?
Do the trials report it?

Useful for all those who still read full paper of trials.( not just abstracts and press release)
Rare nowadays.”

More posts featuring Amol Akhade on oncodaily.com

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.